TY  - JOUR
A1  - Mücke, Marcus Maximilian
A1  - Mücke, Victoria Therese
A1  - Peiffer, Kai-Henrik
A1  - Sarrazin, Christoph
A1  - Zeuzem, Stefan
A1  - Berger, Annemarie
A1  - Vermehren, Johannes
T1  - Absence of HBV reactivation in patients with resolved HBV infection following DAA therapy for hepatitis C : a 1-year follow-up study
T2  - Open Forum Infectious Diseases
N2  - Background: Patients with chronic hepatitis C virus (HCV) infection and active or previous hepatitis B virus (HBV) are at risk of HBV reactivation (HBV-R) during direct-acting antiviral (DAA) therapy. Recent reports suggest that HBV-R may even occur several months after completion of DAA therapy. The aim of this study was to assess the risk of HBV-R in patients with resolved HBV after successful DAA therapy during long-term follow-up (FU).
Methods: Among 848 patients treated for chronic HCV, all patients with resolved HBV and long-term FU data were eligible for inclusion. Patients were HBV DNA/hepatitis B surface antigen (HBsAg)–negative at the end of therapy (EOT) and were followed for up to 52 weeks thereafter. Patients underwent regular alanine transaminase (ALT) testing, and additional HBV DNA/HBsAg testing was performed at FU week 12, end of FU, and in case of an ALT increase above the upper limit of normal (>ULN).
Results: A total of 108 patients were followed up for a mean (range) of 41.5 (24–52) weeks after EOT. None of the patients experienced reverse HBsAg seroconversion or reappearance of HBV DNA. One patient received a liver transplantation; 1 patient was diagnosed with de novo hepatocellular carcinoma, and 2 patients died. Eighteen patients (16.7%) had increased ALT levels (grade 0/1). Of those, the majority were male (72.2%) and significantly more patients had cirrhosis (66.7% vs 36.2%, P = .015) or received ribavirin as part of their treatment regimen (86.7% vs 46.8%, P = .041). None of these were associated with HBV-R.
Conclusions: Our results indicate that the risk of HBV-R in patients with resolved HBV treated with DAAs for HCV is low during long-term follow-up.
KW  - hepatitis B virus
KW  - hepatitis C virus
KW  - HBV reactivation
KW  - HCV treatment
KW  - direct-acting antivirals
KW  - long-term follow-up
Y1  - 2018
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/48860
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-488603
SN  - 2328-8957
N1  - This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
VL  - 6
IS  - 1, ofy340
SP  - 1
EP  - 5
PB  - Oxford University Press
CY  - Oxford
ER  -